Prostate cancer and vitamin D: what does the evidence really suggest? (Q53413194)

14 May 2018

title

Prostate cancer and vitamin D: what does the evidence really suggest? (English)

1 reference

14 May 2018

0 references

2

Tomasz M Beer

1 reference

14 May 2018

author name string

Christine M Barnett

series ordinal

1

1 reference

14 May 2018

publication date

14 June 2011

1 reference

14 May 2018

Urologic Clinics of North America

published in

1 reference

14 May 2018

volume

38

1 reference

14 May 2018

issue

3

1 reference

14 May 2018

page(s)

333-342

1 reference

14 May 2018

Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2011.04.007

Exposure to ultraviolet radiation: association with susceptibility and age at presentation with prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2011.04.007

An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet-B radiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2011.04.007

Susceptibility to prostate cancer: studies on interactions between UVR exposure and skin type

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2011.04.007

Sun exposure, vitamin D receptor gene polymorphisms, and risk of advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2011.04.007

UV, latitude, and spatial trends in prostate cancer mortality: All sunlight is not the same (United States)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2011.04.007

Prostatic 25-hydroxyvitamin D-1alpha-hydroxylase and its implication in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2011.04.007

A single up-stream element confers responsiveness to 1,25-dihydroxyvitamin D3 and tumor necrosis factor-alpha in the rat osteocalcin gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2011.04.007

Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2011.04.007

Identification of a functional vitamin D response element in the human insulin-like growth factor binding protein-3 promoter

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2011.04.007

Modulation of TNF-alpha expression in bone marrow macrophages: involvement of vitamin D response element

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2011.04.007

Identification and characterization of a response element in the EGFR promoter that mediates transcriptional repression by 1,25-dihydroxyvitamin D3 in breast cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2011.04.007

Antiproliferative effect of 1alpha,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2011.04.007

Vitamin D receptor-dependent antitumour effects of 1,25-dihydroxyvitamin D3 and two synthetic analogues in three in vivo models of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2011.04.007

25-Hydroxyvitamin D-1alpha-hydroxylase activity is diminished in human prostate cancer cells and is enhanced by gene transfer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2011.04.007

Vitamin D3 from sunlight may improve the prognosis of breast-, colon- and prostate cancer (Norway).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2011.04.007

Prostate cancer survival is dependent on season of diagnosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2011.04.007

Dairy Products, Calcium Intake, and Risk of Prostate Cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2011.04.007

Calcium, Dairy Foods, and Risk of Incident and Fatal Prostate Cancer: The NIH-AARP Diet and Health Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2011.04.007

Diet and prostate cancer risk in a cohort of smokers, with a specific focus on calcium and phosphorus (Finland)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2011.04.007

Risk of prostate cancer in a randomized clinical trial of calcium supplementation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2011.04.007

Calcium intake and prostate cancer risk in a long-term aging study: the Baltimore Longitudinal Study of Aging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2011.04.007

Calcium, dairy products, and the risk of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2011.04.007

Dietary Intake of Calcium, Vitamin D, Phosphorus and the Risk of Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2011.04.007

Diet, supplement use, and prostate cancer risk: results from the prostate cancer prevention trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2011.04.007

Dairy products, calcium, phosphorous, vitamin D, and risk of prostate cancer (Sweden)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2011.04.007

Prospective Study of Predictors of Vitamin D Status and Cancer Incidence and Mortality in Men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2011.04.007

Serum calcium and incident and fatal prostate cancer in the National Health and Nutrition Examination Survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2011.04.007

Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: A longitudinal, nested case‐control study in the Nordic countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2011.04.007

Serum vitamin D concentration and prostate cancer risk: a nested case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2011.04.007

Vitamin D pathway gene variants and prostate cancer prognosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2011.04.007

Vitamin D receptor (VDR) gene polymorphisms and haplotypes, interactions with plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, and prostate cancer risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2011.04.007

Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2011.04.007

Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2011.04.007

High-dose calcitriol and carboplatin in metastatic androgen-independent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2011.04.007

Phase II trial of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2011.04.007

A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2011.04.007

Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2011.04.007

A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2011.04.007

Prostate cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, United States)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2011.04.007

Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2011.04.007

Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2011.04.007

Plasma levels of 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D and the risk of prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2011.04.007

Lack of association between serum levels of 25-hydroxyvitamin D and the subsequent risk of prostate cancer in Finnish men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2011.04.007

Serum vitamin D and risk of prostate cancer in a case-control analysis nested within the European Prospective Investigation into Cancer and Nutrition (EPIC)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2011.04.007

Serum 25-OH vitamin D levels and risk of developing prostate cancer in older men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2011.04.007

10.1016/J.UCL.2011.04.007

7 January 2021

Identifiers

DOI

1 reference

14 May 2018

1 reference

14 May 2018